Home › Compare › AMANF vs ABBV
AMANF yields 4.77% · ABBV yields 3.06%● Live data
📍 AMANF pulled ahead of the other in Year 2
Combined, AMANF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AMANF + ABBV for your $10,000?
Amano Corporation provides time information, parking, environmental, and cleaning systems in Japan, North America, and internationally. It operates through Time Information System Business and Environment System Business segments. The company's time information systems include time and attendance (T&A), payroll, human resource, and access information systems; and T&A and access information terminals, PC interfaced time recorders, time recorders, electronic time stamps, and T&A/payroll/HR cloud services. It also provides parking systems, such as gate-type, flap-lock, bicycle parking, vehicle guidance, parking lot management, and security gate systems, as well as offers parking facility data center and commissioned management services. In addition, the company offers environmental systems comprising energy and space-saving pulse-jet, all stainless steel body, and dust explosion pressure diffusion type dust collectors; electric mist collectors; dust collectors for welding work; industrial air purifiers; and volatile organic compounds removal, pneumatic powder conveying, and large-scale dust collection systems. Further, it provides cleaning systems that include compact automatic floor and ride-on automatic scrubbers; robotic vacuum, carpet, and industrial vacuum cleaners; and electrolytic water generators, electronic high-speed burnishers, hand-pushed sweepers, and floor polishers. Amano Corporation was founded in 1931 and is headquartered in Yokohama, Japan.
Full AMANF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.